Background An enhanced renin-angiotensin system causes hypertensive renal damage.
Factor Xa not only functions in the coagulation cascade but also activates intracellular signaling through
protease-activated receptors ( PAR ). We investigated the effects of
rivaroxaban,
a factor Xa inhibitor, on hypertensive renal damage in hypertensive mice overexpressing
renin (Ren-TG). Methods and Results The 12- to 16-week-old Ren-TG and wild-type mice were orally administered with or without 6 or 12 mg/kg of
rivaroxaban for 1 or 4 months. Plasma
factor Xa was significantly increased in the Ren-TG compared with the wild-type mice and was reduced by 12 mg/kg of
rivaroxaban ( P<0.05). Urinary
albumin excretion (UAE) was higher in the nontreated 8-month-old Ren-TG than in the wild-type mice (69.6±29 versus 20.1±8.2 μg/day; P<0.01). Treatment with 12 mg/kg of
rivaroxaban for 4 months decreased the UAE to 38.1±13.2 μg/day ( P<0.01). Moreover,
rivaroxaban treatment attenuated histologic changes of glomerular
hypertrophy, mesangial matrix expansion, effacement of the podocyte foot process, and thickened glomerular basement membrane in the Ren-TG. The renal expression of PAR -2 was increased in the Ren-TG, but was inhibited with
rivaroxaban treatment. In vitro study using the human podocytes showed that the expressions of PAR -2 and inflammatory genes and nuclear factor--κB activation were induced by
angiotensin II stimulation, but were inhibited by
rivaroxaban. PAR -2 knockdown by
small interfering RNA also attenuated the PAR -2-related inflammatory gene expressions. Conclusions These findings indicate that
rivaroxaban exerts protective effects against
angiotensin II-induced renal damage, partly through inhibition of the PAR -2 signaling-mediated inflammatory response.